entera

Nov 05, 2019

Frost & Sullivan: Major Drug Companies are Securing an Edge by Leveraging the 505(b)(2) Pathway

Oct 07, 2019

Introducing Investors to Breakthrough Hi-tech and Bio-tech Companies: Frost & Sullivan Publishes Q2 Coverage for Investors to Make Informed Decisions

Jul 01, 2019

From Injections to Pills - Entera Bio (ENTX): Initiation of Coverage by Frost & Sullivan

Dec 12, 2018

Frost & Sullivan Publishes Immediate Report on DNA Biomedical Solutions Ltd.

Dec 03, 2018

eCube Systems Wins Two More Awards in 2018: Most Advanced Legacy Modernization Company and Best Mainframe Distributed Development Environment for NXTware Remote

Jul 03, 2018

Frost & Sullivan Publishes Q-1 Update Coverage Report on DNA Biomedical Solutions Ltd.: Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; Target price remains unchanged.

Feb 06, 2018

Frost & Sullivan Publishes Update Coverage Report on DNA Biomedical Solutions Ltd.: Entera's unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.